GlassScriptPhysician profile
David Thomas Wenk
NPI 1508087297
$15,284.79
in general payments reported to CMS, 2019-2025
74 companies · $1,627 in 2025
The $1,627 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,022 · 2020: $2,114 · 2021: $1,404 · 2022: $2,013 · 2023: $1,937 · 2024: $2,168 · 2025: $1,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,205 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $512 · Education: $14.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,205.41 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $512.28 |
| Education | $14.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,984.82 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Novartis Pharmaceuticals Corporation | $1,104.18 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $989.23 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| Pfizer INC. | $939.30 | 2019-2025 | |
| Janssen Biotech, INC. | $850.30 | 2019-2025 | Darzalex, Tecvayli, Imbruvica |
| Genzyme Corporation | $668.31 | 2019-2025 | |
| Daiichi Sankyo INC. | $661.98 | 2020-2025 | Enhertu, Datroway |
| Celgene Corporation | $607.02 | 2019-2025 | Pomalyst, Reblozyl, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $554.51 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Genentech USA, INC. | $482.90 | 2019-2022 | |
| Abbvie INC. | $478.03 | 2019-2025 | Venclexta |
| Gilead Sciences, INC. | $441.38 | 2019-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $429.23 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $414.21 | 2019-2025 | Keytruda, Lynparza |
| Seagen INC. | $376.84 | 2019-2023 | Tivdak, Tukysa |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wenk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.